Prostate Cancer Clinical Trial

Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

Summary

The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participant must have metastatic prostate cancer for which castration (medical or surgical) is no longer effective (castration-resistant).
Participant must have disease spread to soft tissue that is measurable.
Participant must have documented evidence of progressive disease by PSA test or imaging.
Participant must have previously received at least one of the following treatment: abiraterone acetate, apalutamide, darolutamide or enzalutamide.
Participant must have previously received chemotherapy with docetaxel and cabazitaxel.
Participant must be willing and amenable to undergo a biopsy of tumor tissue (or able to provide adequate archived tumor tissue sample) and to provide blood for research.
Participant must have good physical functioning ability and adequate organ function.

Exclusion Criteria:

Participant must not have received more than 3 therapy regimens for metastatic castration-resistant prostate cancer (NOTE: GnRHa, first-generation antiandrogens (flutamide, nilutamide, or bicalutamide), diethylstilbestrol (DES) (or other estrogens), corticosteroids, ketoconazole, and bone loss-prevention will not count as systemic therapy regimens.
Participants must not have previously received abemaciclib or any cyclin-dependent kinase (CDK)4 and/or CDK6 inhibitors.
Participants must not have serious and/or uncontrolled preexisting medical condition(s) including but not limited to severe renal impairment, severe hepatic impairment, interstitial lung disease (ILD)/pneumonitis, severe dyspnea at rest or requiring oxygen therapy or other serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.
Participants must not have, or suspected to have, brain metastasis.
Participants must not have untreated spinal cord compression, evidence of spinal metastases with risk of spinal compression or structurally unstable bone lesions suggesting impending fracture.

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

44

Study ID:

NCT04408924

Recruitment Status:

Completed

Sponsor:

Eli Lilly and Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 14 Locations for this study

See Locations Near You

University of Utah - Huntsman Cancer Institute
Salt Lake City Utah, 84112, United States
Seattle Cancer Care Alliance
Seattle Washington, 98109, United States
Centre Leon Berard
Lyon Cedex 08 , 69373, France
Institut Paoli-Calmettes
Marseille , 13273, France
Hopital Europeen Georges Pompidou
Paris , 75015, France
Institut Claudius Regaud
Toulouse cedex 9 , 31059, France
Gustave Roussy
Villejuif Cedex , 94805, France
Institut Catala d'Oncologia
L'Hospitalet de Llobregat Barcelona, 08907, Spain
Corporacion Sanitaria Parc Tauli
Sabadell Barcelona, 08208, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona , 08025, Spain
Hospital Universitari Vall d'Hebron
Barcelona , 08035, Spain
Hospital General Universitario Gregorio Maranon
Madrid , 28007, Spain
Hospital Universitario Ramon y Cajal
Madrid , 28034, Spain
Hospital Universitario 12 de Octubre
Madrid , 28041, Spain

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

44

Study ID:

NCT04408924

Recruitment Status:

Completed

Sponsor:


Eli Lilly and Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.